B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

PURPOSE: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. Data on mutation rates in patients without PD on ibrutinib tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Woyach, Jennifer A., Ghia, Paolo, Byrd, John C., Ahn, Inhye E., Moreno, Carol, O'Brien, Susan M., Jones, Daniel, Cheung, Leo W.K., Chong, Elizabeth, Kwei, Kevin, Dean, James P., James, Danelle F., Wiestner, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425728/
https://www.ncbi.nlm.nih.gov/pubmed/37314786
http://dx.doi.org/10.1158/1078-0432.CCR-22-3887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425728/
https://www.ncbi.nlm.nih.gov/pubmed/37314786
http://dx.doi.org/10.1158/1078-0432.CCR-22-3887

Ejemplares similares